IL-1ꞵ is largely thought to promote tumor growth, and the vast majority of IL-1β-based therapies aim to block the cytokine and its signaling, while IL-18 is largely thought to promote antitumor immune responses, and many therapeutic efforts aim to boost IL-18 signaling. This evidence concerns the gene IL1A and neoplasm.